rs181912750
Variant names:
Variant summary
Our verdict is Benign. The variant received -11 ACMG points: 3P and 14B. PM1PP3BP4_StrongBP6_ModerateBS1BS2
The NM_002047.4(GARS1):c.1724T>C(p.Ile575Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000363 in 1,612,408 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.00064 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00033 ( 0 hom. )
Consequence
GARS1
NM_002047.4 missense
NM_002047.4 missense
Scores
9
6
3
Clinical Significance
Conservation
PhyloP100: 7.99
Publications
0 publications found
Genes affected
GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]
GARS1 Gene-Disease associations (from GenCC):
- Charcot-Marie-Tooth disease type 2DInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- neuronopathy, distal hereditary motor, type 5AInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Illumina, Laboratory for Molecular Medicine
- spinal muscular atrophy, infantile, James typeInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -11 ACMG points.
PM1
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 6 uncertain in NM_002047.4
PP3
Multiple lines of computational evidence support a deleterious effect 9: AlphaMissense, BayesDel_noAF, Cadd, Eigen, FATHMM_MKL, phyloP100way_vertebrate, PROVEAN, REVEL, REVEL [when BayesDel_addAF, max_spliceai, MetaRNN, MutationTaster was below the threshold]
BP4
Computational evidence support a benign effect (MetaRNN=0.057784617).
BP6
Variant 7-30628584-T-C is Benign according to our data. Variant chr7-30628584-T-C is described in ClinVar as [Benign]. Clinvar id is 416089.Status of the report is criteria_provided_single_submitter, 1 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.000643 (98/152366) while in subpopulation NFE AF = 0.00025 (17/68030). AF 95% confidence interval is 0.000159. There are 1 homozygotes in GnomAd4. There are 71 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 98 AD gene.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.1724T>C | p.Ile575Thr | missense_variant | Exon 14 of 17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
GARS1 | ENST00000675651.1 | c.1724T>C | p.Ile575Thr | missense_variant | Exon 14 of 17 | ENSP00000502513.1 | ||||
GARS1 | ENST00000675810.1 | c.1622T>C | p.Ile541Thr | missense_variant | Exon 13 of 16 | ENSP00000502743.1 | ||||
GARS1 | ENST00000675693.1 | c.1556T>C | p.Ile519Thr | missense_variant | Exon 15 of 18 | ENSP00000502174.1 | ||||
GARS1 | ENST00000675051.1 | c.1523T>C | p.Ile508Thr | missense_variant | Exon 14 of 17 | ENSP00000502296.1 | ||||
GARS1 | ENST00000674815.1 | c.1355T>C | p.Ile452Thr | missense_variant | Exon 14 of 17 | ENSP00000502799.1 | ||||
GARS1 | ENST00000674851.1 | c.1355T>C | p.Ile452Thr | missense_variant | Exon 15 of 18 | ENSP00000502451.1 | ||||
GARS1 | ENST00000444666.6 | n.*145T>C | non_coding_transcript_exon_variant | Exon 15 of 18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*1438T>C | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*824T>C | non_coding_transcript_exon_variant | Exon 15 of 17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*1062T>C | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.1638T>C | non_coding_transcript_exon_variant | Exon 13 of 16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*1594T>C | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.1638T>C | non_coding_transcript_exon_variant | Exon 13 of 15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*1666T>C | non_coding_transcript_exon_variant | Exon 16 of 19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*669T>C | non_coding_transcript_exon_variant | Exon 14 of 17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*1175T>C | non_coding_transcript_exon_variant | Exon 14 of 17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*1013T>C | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*1156T>C | non_coding_transcript_exon_variant | Exon 14 of 17 | ENSP00000501980.1 | |||||
GARS1 | ENST00000676403.1 | n.1724T>C | non_coding_transcript_exon_variant | Exon 14 of 16 | ENSP00000502681.1 | |||||
GARS1 | ENST00000444666.6 | n.*145T>C | 3_prime_UTR_variant | Exon 15 of 18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*1438T>C | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*824T>C | 3_prime_UTR_variant | Exon 15 of 17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*1062T>C | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000675529.1 | n.*1594T>C | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000676088.1 | n.*1666T>C | 3_prime_UTR_variant | Exon 16 of 19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*669T>C | 3_prime_UTR_variant | Exon 14 of 17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*1175T>C | 3_prime_UTR_variant | Exon 14 of 17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*1013T>C | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*1156T>C | 3_prime_UTR_variant | Exon 14 of 17 | ENSP00000501980.1 |
Frequencies
GnomAD3 genomes AF: 0.000644 AC: 98AN: 152248Hom.: 1 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
98
AN:
152248
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.000817 AC: 204AN: 249582 AF XY: 0.000687 show subpopulations
GnomAD2 exomes
AF:
AC:
204
AN:
249582
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000334 AC: 488AN: 1460042Hom.: 0 Cov.: 30 AF XY: 0.000314 AC XY: 228AN XY: 726346 show subpopulations
GnomAD4 exome
AF:
AC:
488
AN:
1460042
Hom.:
Cov.:
30
AF XY:
AC XY:
228
AN XY:
726346
show subpopulations
African (AFR)
AF:
AC:
0
AN:
33442
American (AMR)
AF:
AC:
3
AN:
44700
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
26080
East Asian (EAS)
AF:
AC:
1
AN:
39640
South Asian (SAS)
AF:
AC:
0
AN:
86236
European-Finnish (FIN)
AF:
AC:
423
AN:
53382
Middle Eastern (MID)
AF:
AC:
0
AN:
5754
European-Non Finnish (NFE)
AF:
AC:
45
AN:
1110510
Other (OTH)
AF:
AC:
16
AN:
60298
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.478
Heterozygous variant carriers
0
25
50
76
101
126
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.000643 AC: 98AN: 152366Hom.: 1 Cov.: 32 AF XY: 0.000953 AC XY: 71AN XY: 74512 show subpopulations
GnomAD4 genome
AF:
AC:
98
AN:
152366
Hom.:
Cov.:
32
AF XY:
AC XY:
71
AN XY:
74512
show subpopulations
African (AFR)
AF:
AC:
1
AN:
41590
American (AMR)
AF:
AC:
0
AN:
15306
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3472
East Asian (EAS)
AF:
AC:
0
AN:
5190
South Asian (SAS)
AF:
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
AC:
80
AN:
10628
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
17
AN:
68030
Other (OTH)
AF:
AC:
0
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.497
Heterozygous variant carriers
0
5
10
16
21
26
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
64
ClinVar
Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Charcot-Marie-Tooth disease type 2 Benign:1
Feb 12, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D
M_CAP
Uncertain
D
MetaRNN
Benign
T
MetaSVM
Uncertain
T
PhyloP100
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.